WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATCvet code alterations

Previous ATCvet codeATCvet level name New ATCvet code
QL01EX16erdafitinibQL01EN01
QL01EX20pemigatinibQL01EN02
QL01XCMonoclonal antibodiesdeleted
QL01XC01edrecolomabQL01FX01
QL01XC02rituximabQL01FA01
QL01XC03trastuzumabQL01FD01
QL01XC05gemtuzumab ozogamicinQL01FX02
QL01XC06cetuximabQL01FE01
QL01XC07bevacizumabQL01FG01
QL01XC08panitumumabQL01FE02
QL01XC09catumaxomabQL01FX03
QL01XC10ofatumumabQL01FA02
QL01XC11ipilimumabQL01FX04
QL01XC12brentuximab vedotinQL01FX05
QL01XC13pertuzumabQL01FD02
QL01XC14trastuzumab emtansineQL01FD03
QL01XC15obinutuzumabQL01FA03
QL01XC16dinutuximab betaQL01FX06
QL01XC17nivolumabQL01FF01
QL01XC18pembrolizumabQL01FF02
QL01XC19blinatumomabQL01FX07
QL01XC21ramucirumabQL01FG02
QL01XC22necitumumabQL01FE03
QL01XC23elotuzumabQL01FX08
QL01XC24daratumumabQL01FC01
QL01XC25mogamulizumabQL01FX09
QL01XC26inotuzumab ozogamicinQL01FB01
QL01XC27olaratumabQL01FX10
QL01XC28durvalumabQL01FF03
QL01XC29bermekimabQL01FX11
QL01XC31avelumabQL01FF04
QL01XC32atezolizumabQL01FF05
QL01XC33cemiplimabQL01FF06
QL01XC34moxetumomab pasudotoxQL01FB02
QL01XC35tafasitamabQL01FX12
QL01XC36enfortumab vedotinQL01FX13
QL01XC37polatuzumab vedotinQL01FX14
QL01XC38isatuximabQL01FC02
QL01XC39belantamab mafodotinQL01FX15
QL01XC40dostarlimabQL01FF07
QL01XC41trastuzumab deruxtecanQL01FD04
QL01XC42prolgolimabQL01FF08

Last updated: 2021-12-17